Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target by Van Houdt, WJ, Emmink, BL, Pham, TV, Piersma, SR, Verheem, A, Vries, RG, Fratantoni, SA, Pronk, A, Clevers, H, Borel Rinkes, IHM, Jimenez, CR, Kranenburg, O

Get full text

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomise... by Rozeman, Elisa A, Menzies, Alexander M, van Akkooi, Alexander C J, Adhikari, Chandra, Bierman, Carolien, van de Wiel, Bart A, Scolyer, Richard A, Krijgsman, Oscar, Sikorska, Karolina, Eriksson, Hanna, Broeks, Annegien, van Thienen, Johannes V, Guminski, Alexander D, Acosta, Alex Torres, ter Meulen, Sylvia, Koenen, Anne Miek, Bosch, Linda J W, Shannon, Kerwin, Pronk, Loes M, Gonzalez, Maria, Ch'ng, Sydney, Grijpink-Ongering, Lindsay G, Stretch, Jonathan, Heijmink, Stijn, van Tinteren, Harm, Haanen, John B A G, Nieweg, Omgo E, Klop, Willem M C, Zuur, Charlotte L, Saw, Robyn P M, van Houdt, Winan J, Peeper, Daniel S, Spillane, Andrew J, Hansson, Johan, Schumacher, Ton N, Long, Georgina V, Blank, Christian U

Get full text

Erratum to: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group by Ahlen, Jan, Ahuja, Nita, Antbacka, Robert, Bagaria, Sanjay, Blay, Jean-Yves, Bonvalot, Sylvie, Callegaro, Dario, Canter, Robert J, Cardona, Kenneth, Casali, Paolo G, Colombo, Chiara, Dei Tos, Angelo P, De Paoli, Antonino, Desai, Anant, Dickson, Brendan C, Eilber, Fritz C, Fiore, Marco, Fletcher, Cristopher D, d, Samuel J, Gelderblom, Hans J, Gonzalez, Ricardo, Grignani, Giovanni, Grignol, Valerie, Gronchi, Alessandro, Haas, Rick L, Hayes, Andrew J, Hartmann, Wolfgang, Henzler, Thomas, Hohenberger, Peter, Italiano, Antoine, Jakob, Jens, Jones, Robin L, Judson, Ian, John M Kane 3rd, Lahat, Guy, MacNeill, Andrea J, Maestro, Roberta, Messiou, Christina, Meeus, Pierre, Miceli, Rosalba, Mullen, John T, Nessim, Carolyn, Pennacchioli, Elisabetta, Pillarisetty, Vinu G, Pollock, Raphael E, Quagliuolo, Vittorio, Radaelli, Stefano, Raut, Chandrajit P, Rutkowski, Piotr, Sandrucci, Sergio, Schrage, Yvonne M, Sicklick, Jason K, Smith, Myles J, Stacchiotti, Silvia, Eberhardt Stoeckle, Strauss, Dirk C, Swallow, Carol J, Tseng, William, Wardelmann, Eva, Frits van Coevorden, van Houdt, Winan J, Wasif, Nabil

Get full text

36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials by Blank, CU, Versluis, JM, Rozeman, EA, Menzies, AM, Reijers, IL, Krijgsman, O, Hoefsmit, EP, van de Wiel, BA, Sikorska, K, Bierman, C, Dimitriadis, P, Gonzalez, M, Broeks, A, Kerkhoven, RM, Spillane, AJ, Haanen, JB, van Houdt, WJ, Saw, RP, Eriksson, H, van Akkooi, AC, Scolyer, RA, Schumacher, TN, Long, GV

Get full text

Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter by Haviv, Yosef S, van Houdt, Winan J, Lu, Baogen, Curiel, David T, Zhu, Zeng B

Get full text

L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patient... by Versluis, J M, Rozeman, E A, Menzies, A M, Reijers, ILM, Krijgsman, O, Hoefsmit, E P, BA van de Wiel, Sikorska, K, Bierman, C, Dimitriadis, P, Gonzalez, M, Broeks, A, Kerkhoven, R M, Spillane, A J, Haanen, JBAG, WJ van Houdt, Saw, RPM, Eriksson, H, ACJ van Akkooi, Scolyer, R A, Schumacher, T N, Long, G V, Blank, C U

Get full text